-transparent.png){kind=logo}
Plasma fibronectin was determined by laser nephelometric immunoassay in two populations: healthy individuals and patients with metastatic or non-metastatic breast cancer. The results showed that the fibronectin concentration was higher in the patient group than in the healthy controls of similar age, with a significant difference (p less than 0.05). The patients who had metastatic breast cancer tended to show higher levels than those with no detectable metastasis, but such a difference was not statistically significant. Since fibronectin is sensitive to clinical events unrelated to the malignancy status, it does not seem suitable as a tumor marker.
Related Publications
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
November 1987,
No to shinkei = Brain and nerve,
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
January 1984,
Terapevticheskii arkhiv,
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
January 1985,
Terapevticheskii arkhiv,
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
January 1991,
Voprosy onkologii,
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
March 1983,
Cancer,
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
January 1988,
Medecine interne,
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
January 1990,
Acta medica Austriaca,
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
February 1983,
Presse medicale (Paris, France : 1983),
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
October 1985,
Clinica chimica acta; international journal of clinical chemistry,
A Ruelland, and
P Kerbrat, and
C Clerc, and
B Legras, and
L Cloarec
January 1991,
Vestnik Akademii meditsinskikh nauk SSSR,
